Oritavancin CAS NO 192564-14-0 Inquire about Oritavancin

Tecoland supplies Oritavancin bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Oritavancin is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Oritavancin?

Oritavancin (also known as LY333328, Orbactiv) is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections. Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005.

In December 2008, the US Food and Drug Administration declined to approve it without additional studies, and an EU application was withdrawn. In 2009, the development rights were acquired by The Medicines Company, which has completed clinical trials and submitted a new drug application to the FDA in February 2014. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections in the United States.

Its chemical structure is similar to vancomycin. It is a lipoglycopeptide.

Mechanism of action

The 4′-chlorobiphenylmethyl group disrupts the cell membrane of Gram-positive bacteria. It also acts by inhibition of transglycosylation and inhibition of transpeptidation.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.